Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates

Shares of Amneal Pharmaceuticals (AMRX) , a commercial-stage company marketing generics as well as specialty pharmaceutical products for several therapeutic areas, including neurology and endocrinology, have soared 29.3% in the past month after the company announced back-to-back regulatory approvals.Amneal Gets FDA Nod for Parkinson’s Disease DrugIn August 2024, the FDA approved Amneal’s IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and ex ...